This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Reed, J. C. Articles by Cohen, J. Search for Related Content PubMed PubMed Citation Articles by Reed, J. C. Articles by Cohen, J.

Antisense-mediated Inhibition of BCL2 Protooncogene Expression and Leukemic Cell Growth and Survival: Comparisons of Phosphodiester and Phosphorothioate Oligodeoxynucleotides¹

Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104-6082 [J. C. R., S. Y.]; Clinical Pharmacology Branch, National Cancer Institute, Bethesda, Maryland 20892 [C. S., C. S., J. C.]; and Fels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, Philadelphia, Pennsylvania 19140 [S. H., C. M. C.]

Antisense oligodeoxynucleotides specific for sequences in mRNAs from the B-cell lymphoma/leukemia-2 (BCL2) gene were used to inhibit the growth in culture of a human leukemia cell line, 697. Normal phosphodiester (PO) and nuclease-resistant phosphorothioate (PS) oligodeoxynucleotides were compared with regard to specificity, potency, and kinetics. Both PO and PS antisense BCL2 oligodeoxynucleotides were specific inhibitors of cellular proliferation, since sense versions of these synthetic DNAs were inactive at similar concentrations. Specificity was further confirmed by quantitative immunofluorescence studies, showing that PO and PS antisense BCL2 oligodeoxynucleotides (when used at appropriate concentrations) reduced levels of BCL2 protein without influencing expression of HLA-DR and other control antigens. The onset of inhibition by PO oligodeoxynucleotides was faster, with reductions in cell numbers occurring within 1 day of addition to cultures, in contrast to phosphorothioates, which were ineffective until 3–4 days. Phosphorothioates were more potent that phosphodiesters, however, with half-maximal inhibition of leukemic cell growth occurring at concentrations 5–10 times lower. As expected from previous studies demonstrating the importance of BCL2 for regulating lymphoid cell survival, BCL2 antisense oligodeoxynucleotides also led to 697 leukemic cell death through sequence-specific mechanisms, with reductions in cellular viability generally lagging the inhibitory effects on cellular growth by about 2 days. Taken together, these data indicate that PO and PS oligodeoxynucleotides targeted against the human BCL2 protooncogene can be sequencespecific inhibitors of leukemic cell growth and survival.

¹ Supported in part by grants CA-47946 from the NIH, a Special Fellowship from the Leukemia Society of America (J. C. R.), and the Lucille P. Markey Charitable Trust.

² To whom requests for reprints should be addressed, at Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104-6082.

Received 11/16/88. Accepted 6/27/90.

This article has been cited by other articles:

				S. Kim, U. J. Lee, M. N. Kim, E.-J. Lee, J. Y. Kim, M. Y. Lee, S. Choung, Y. J. Kim, and Y.-C. Choi MicroRNA miR-199a* Regulates the MET Proto-oncogene and the Downstream Extracellular Signal-regulated Kinase 2 (ERK2) J. Biol. Chem., June 27, 2008; 283(26): 18158 - 18166. [Abstract] [Full Text] [PDF]

				J. C. Reed Bcl-2-family proteins and hematologic malignancies: history and future prospects Blood, April 1, 2008; 111(7): 3322 - 3330. [Abstract] [Full Text] [PDF]

				S. Kitada, C. L. Kress, M. Krajewska, L. Jia, M. Pellecchia, and J. C. Reed Bcl-2 antagonist apogossypol (NSC736630) displays single-agent activity in Bcl-2-transgenic mice and has superior efficacy with less toxicity compared with gossypol (NSC19048) Blood, March 15, 2008; 111(6): 3211 - 3219. [Abstract] [Full Text] [PDF]

				C. M. Rudin, R. Salgia, X. Wang, L. D. Hodgson, G. A. Masters, M. Green, and E. E. Vokes Randomized Phase II Study of Carboplatin and Etoposide With or Without the bcl-2 Antisense Oligonucleotide Oblimersen for Extensive-Stage Small-Cell Lung Cancer: CALGB 30103 J. Clin. Oncol., February 20, 2008; 26(6): 870 - 876. [Abstract] [Full Text] [PDF]

				B. E. Johnson, C. M. Rudin, and R. Salgia Novel and Targeted Agents for Small Cell Lung Cancer ASCO Educational Book, January 1, 2008; 2008(1): 363 - 367. [Abstract] [Full Text] [PDF]

				S. R. Rheingold, M. D. Hogarty, S. M. Blaney, J. A. Zwiebel, C. Sauk-Schubert, R. Chandula, M. D. Krailo, and P. C. Adamson Phase I Trial of G3139, a bcl-2 Antisense Oligonucleotide, Combined With Doxorubicin and Cyclophosphamide in Children With Relapsed Solid Tumors: A Children's Oncology Group Study J. Clin. Oncol., April 20, 2007; 25(12): 1512 - 1518. [Abstract] [Full Text] [PDF]

				K. W. Yip, J. D. Mocanu, P.Y. B. Au, G. T. Sleep, D. Huang, P. Busson, W.-C. Yeh, R. Gilbert, B. O'Sullivan, P. Gullane, et al. Combination Bcl-2 Antisense and Radiation Therapy for Nasopharyngeal Cancer Clin. Cancer Res., November 15, 2005; 11(22): 8131 - 8144. [Abstract] [Full Text] [PDF]

				J. C. Reed and M. Pellecchia Apoptosis-based therapies for hematologic malignancies Blood, July 15, 2005; 106(2): 408 - 418. [Abstract] [Full Text] [PDF]

				U. Fischer and K. Schulze-Osthoff New Approaches and Therapeutics Targeting Apoptosis in Disease Pharmacol. Rev., June 1, 2005; 57(2): 187 - 215. [Abstract] [Full Text] [PDF]

				C. M. Rudin, M. Kozloff, P. C. Hoffman, M. J. Edelman, R. Karnauskas, R. Tomek, L. Szeto, and E. E. Vokes Phase I Study of G3139, a bcl-2 Antisense Oligonucleotide, Combined With Carboplatin and Etoposide in Patients With Small-Cell Lung Cancer J. Clin. Oncol., March 15, 2004; 22(6): 1110 - 1117. [Abstract] [Full Text] [PDF]

				A. Bevilacqua, M. C. Ceriani, G. Canti, L. Asnaghi, R. Gherzi, G. Brewer, L. Papucci, N. Schiavone, S. Capaccioli, and A. Nicolin Bcl-2 Protein Is Required for the Adenine/Uridine-rich Element (ARE)-dependent Degradation of Its Own Messenger J. Biol. Chem., June 20, 2003; 278(26): 23451 - 23459. [Abstract] [Full Text] [PDF]

				B. Jahrsdorfer, R. Jox, L. Muhlenhoff, K. Tschoep, A. Krug, S. Rothenfusser, G. Meinhardt, B. Emmerich, S. Endres, and G. Hartmann Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN J. Leukoc. Biol., July 1, 2002; 72(1): 83 - 92. [Abstract] [Full Text] [PDF]

				M. Guzey, S. Kitada, and J. C. Reed Apoptosis Induction by 1{alpha},25-Dihydroxyvitamin D3 in Prostate Cancer Mol. Cancer Ther., July 1, 2002; 1(9): 667 - 677. [Abstract] [Full Text] [PDF]

				C. M. Rudin, G. A. Otterson, A. M. Mauer, M. A. Villalona-Calero, R. Tomek, B. Prange, C. M. George, L. Szeto, and E. E. Vokes A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer Ann. Onc., April 1, 2002; 13(4): 539 - 545. [Abstract] [Full Text] [PDF]

				R. Mohammad, Y. Abubakr, M. Dan, A. Aboukameel, C. Chow, A. Mohamed, N. Hamdy, and A. Al-Katib Bcl-2 Antisense Oligonucleotides Are Effective against Systemic but not Central Nervous System Disease in Severe Combined Immunodeficient Mice Bearing Human t(14;18) Follicular Lymphoma Clin. Cancer Res., April 1, 2002; 8(4): 1277 - 1283. [Abstract] [Full Text] [PDF]

				R. HUANG, T. WU, L. XU, A. LIU, Y. JI, and G. HU Upstream binding factor up-regulated in hepatocellular carcinoma is related to the survival and cisplatin-sensitivity of cancer cells FASEB J, March 1, 2002; 16(3): 293 - 301. [Abstract] [Full Text] [PDF]

				P. S. Schwartz and D. J. Waxman Cyclophosphamide Induces Caspase 9-Dependent Apoptosis in 9L Tumor Cells Mol. Pharmacol., December 1, 2001; 60(6): 1268 - 1279. [Abstract] [Full Text] [PDF]

				M. R. Smith, T. Xie, Z.-Z. Zhou, and I. Joshi Efficacy of Treatment with Antisense Oligonucleotides Complementary to Immunoglobulin Sequences of bcl-2/Immunoglobulin Fusion Transcript in a t(14;18) Human Lymphoma-scid Mouse Model Clin. Cancer Res., February 1, 2001; 7(2): 400 - 406. [Abstract] [Full Text]

				C. Sgadari, E. Toschi, C. Palladino, G. Barillari, D. Carlei, A. Cereseto, C. Ciccolella, R. Yarchoan, P. Monini, M. Sturzl, et al. Mechanism of Paclitaxel Activity in Kaposi's Sarcoma J. Immunol., July 1, 2000; 165(1): 509 - 517. [Abstract] [Full Text] [PDF]

				K. Breitschopf, J. Haendeler, P. Malchow, A. M. Zeiher, and S. Dimmeler Posttranslational Modification of Bcl-2 Facilitates Its Proteasome-Dependent Degradation: Molecular Characterization of the Involved Signaling Pathway Mol. Cell. Biol., March 1, 2000; 20(5): 1886 - 1896. [Abstract] [Full Text]

				O. Bairey, Y. Zimra, M. Shaklai, E. Okon, and E. Rabizadeh Bcl-2, Bcl-X, Bax, and Bak Expression in Short- and Long-Lived Patients with Diffuse Large B-Cell Lymphomas Clin. Cancer Res., October 1, 1999; 5(10): 2860 - 2866. [Abstract] [Full Text] [PDF]

				S. Morelli, D. Delia, S. Capaccioli, A. Quattrone, N. Schiavone, A. Bevilacqua, S. Tomasini, and A. Nicolin The antisense bcl-2-IgH transcript is an optimal target for synthetic oligonucleotides PNAS, July 22, 1997; 94(15): 8150 - 8155. [Abstract] [Full Text] [PDF]

				F. I. Raynaud, R. M. Orr, P. M. Goddard, H. A. Lacey, H. Lancashire, I. R. Judson, T. Beck, B. Bryan, and F. E. Cotter Pharmacokinetics of G3139, a Phosphorothioate Oligodeoxynucleotide Antisense to bcl-2, after Intravenous Administration or Continuous Subcutaneous Infusion to Mice J. Pharmacol. Exp. Ther., April 1, 1997; 281(1): 420 - 427. [Abstract] [Full Text]

				M. R. Bennett and S. M. Schwartz Antisense Therapy for Angioplasty Restenosis : Some Critical Considerations Circulation, October 1, 1995; 92(7): 1981 - 1993. [Full Text]

				C. Thompson Apoptosis in the pathogenesis and treatment of disease Science, March 10, 1995; 267(5203): 1456 - 1462. [Abstract] [PDF]

				Q. Lu, A. Hanby, M. Nasser Hajibagheri, S. Gschmeissner, P. Lu, J Taylor-Papadimitriou, S Krajewski, J. Reed, and N. Wright Bcl-2 protein localizes to the chromosomes of mitotic nuclei and is correlated with the cell cycle in cultured epithelial cell lines J. Cell Sci., January 2, 1994; 107(2): 363 - 371. [Abstract] [PDF]